Answers are grounded in this paper and cite their sources.
To describe the patient-level prevalence of recorded pyuria under routine pre-instillation microscopic urinalysis and compare outcomes between two physician-determined screening pathways during bacillus Calmette–Guérin (BCG) induction for non–muscle-invasive bladder cancer. Retrospective cohort of 288 consecutive patients treated at one centre, 2015–2025. Eight urologists administered BCG: four obtained a urinalysis before every instillation (routine pathway, n = 118) and four only when urinary symptoms were present (symptom-triggered, n = 170). Pyuria was defined as more than 5 white cells per high-power field. Outcomes were toxicity, delay of at least 7 days, discontinuation, antibiotic exposure, febrile urinary tract infection (UTI) and recurrence, summarised descriptively as counts, percentages and absolute risk differences; no model-based estimates, confidence intervals or significance tests are reported. Urinalysis was obtained in all 118 routine-pathway patients and in 35 of 170 (20.6%) symptom-triggered patients. In the routine pathway pyuria was recorded in 8 of 118 patients (6.8%), prompting postponement in 1 and antibiotics in none. Grade ≥ 2 toxicity (5.9% vs. 20.0%), treatment delay (1.7% vs. 20.0%) and antibiotic exposure (2.5% vs. 20.0%) were lower in the routine group, with risk differences of − 14.1, − 18.3 and − 17.5% points, respectively, as was febrile UTI (0% vs. 4.7%; −4.7% points); discontinuation (7.6% vs. 5.9%) and recurrence (55.9% vs. 57.4%) were similar. In the symptom-triggered group 28 of 36 affected patients had all three of pyuria, grade ≥ 2 toxicity and delay. Screening pathways were associated with marked differences in recorded toxicity, delay and antibiotic use. Because pathway assignment, management and outcome grading were all physician dependent, and symptoms both triggered testing and defined several outcomes, these differences cannot be attributed to urinalysis itself. Routine urinalysis recorded pyuria infrequently and rarely altered management; whether it should be omitted cannot be settled by these data. Not applicable.
No takes yet. Share an insight, caveat, or question.
Ratchanon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: